NYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis $74.30 +0.34 (+0.45%) Closing price 03:59 PM EasternExtended Trading$74.00 -0.30 (-0.40%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Globus Medical Stock (NYSE:GMED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Globus Medical alerts:Sign Up Key Stats Today's Range$73.70▼$74.9950-Day Range$73.61▼$88.4852-Week Range$54.15▼$101.40Volume1.63 million shsAverage Volume1.48 million shsMarket Capitalization$9.97 billionP/E Ratio19.00Dividend YieldN/APrice Target$101.77Consensus RatingModerate Buy Company Overview Globus Medical, Inc. (NYSE: GMED) is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine. The company’s products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments. Globus Medical also offers technology for computer-assisted surgery, navigation and robotic applications, including its Excelsius platform. Following its combination with NuVasive in 2023, the company expanded its offerings in spine care and added complementary technologies, products and services for orthopedic and neurological procedures. Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and international markets. The company markets its products through direct sales and independent distribution channels, working with surgeons and healthcare institutions to support complex spinal and musculoskeletal procedures.AI Generated. May Contain Errors. Read More Globus Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreGMED MarketRank™: Globus Medical scored higher than 82% of companies evaluated by MarketBeat, and ranked 58th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialGlobus Medical has a consensus price target of $101.77, representing about 37.0% upside from its current price of $74.30.Amount of Analyst CoverageGlobus Medical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Globus Medical's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.02% Earnings GrowthEarnings for Globus Medical are expected to grow by 8.02% in the coming year, from $4.99 to $5.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 19.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 19.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.98.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Globus Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.18% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Globus Medical has recently increased by 2.22%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentGlobus Medical has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Globus Medical this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows7 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,413,400.00 in company stock.Percentage Held by Insiders18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Globus Medical's insider trading history. Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMED Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Ultragenyx Pharmaceutical (RARE) and Globus Medical (GMED)September 19, 2026 | theglobeandmail.comGlobus Medical (GMED) Stock May Trade At A Discount On EarningsSeptember 19, 2026 | finance.yahoo.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 24 at 1:00 AM | Paradigm Press (Ad)James Tobin Sells 30,000 Shares of Globus Medical (NYSE:GMED) StockSeptember 18, 2026 | americanbankingnews.comInsider Move at Globus Medical: Director Executes Major Stock SaleSeptember 16, 2026 | tipranks.comZacks.com featured highlights include Globus Medical, NetApp and AssurantSeptember 10, 2026 | uk.finance.yahoo.comGlobus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging SystemSeptember 4, 2026 | finance.yahoo.comGlobus Medical granted CE mark for mobile X-ray system in EuropeSeptember 4, 2026 | seekingalpha.comSee More Headlines GMED Stock Analysis - Frequently Asked Questions How have GMED shares performed this year? Globus Medical's stock was trading at $87.39 at the start of the year. Since then, GMED stock has decreased by 15.0% and is now trading at $74.2960. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) announced its quarterly earnings data on Thursday, August, 6th. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24. The firm's revenue was up 5.9% on a year-over-year basis. Read the conference call transcript. Is Globus Medical buying back stock? Globus Medical's board approved a share repurchase program on Thursday, May 15th 2025, which permits the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued. When did Globus Medical IPO? Globus Medical (GMED) raised $200 million in an initial public offering on Friday, August 3rd 2012. The company issued 11,764,705 shares at a price of $16.00-$18.00 per share. Who are Globus Medical's major shareholders? Top institutional shareholders of Globus Medical include Paradigm Capital Management Inc. NY (0.65%), American Capital Management Inc. (0.49%), Annex Advisory Services LLC (0.27%) and Varenne Capital Partners (0.18%). Insiders that own company stock include David D Davidar, Stephen T Zarrilli, Ann D Rhoads, James R Tobin, Leslie V Norwalk, Kyle Kline, Kelly Huller, Keith W Pfeil, Daniel T Scavilla and Dan Lemaitre. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, GMED's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:GMED CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees6,000Year Founded2003Price Target and Rating Average Price Target for Globus Medical$101.77 High Price Target$123.00 Low Price Target$80.00 Potential Upside/Downside+37.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$3.91 Trailing P/E Ratio19.00 Forward P/E Ratio14.89 P/E Growth1.21Net Income$537.87 million Net Margins17.02% Pretax Margin20.99% Return on Equity14.57% Return on Assets12.62% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio2.93 Sales & Book Value Annual Sales$2.94 billion Price / Sales3.39 Cash Flow$6.21 per share Price / Cash Flow11.97 Book Value$33.86 per share Price / Book2.19Miscellaneous Outstanding Shares134,260,000Free Float109,585,000Market Cap$9.97 billion OptionableOptionable Beta0.95 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSE:GMED) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
